**PROCEPT BioRobotics Corp. Reports Fiscal Year 2025 Results**

PROCEPT BioRobotics Corporation (PRCT), a surgical robotics company focused on urology, announced its financial results for the fiscal year ended December 31, 2025. The company reported revenue of $308.1 million, a 37% increase compared to $224.5 million in 2024. This growth was primarily driven by increased sales volumes of both its AquaBeam and HYDROS robotic systems and single-use disposable handpieces, which are essential for the Aquablation therapy. Despite the revenue growth, PROCEPT BioRobotics reported a net loss of $95.6 million for 2025, slightly higher than the $91.4 million net loss in the previous year. As of December 31, 2025, the company's accumulated deficit stood at $641.6 million.

A key factor influencing PROCEPT BioRobotics' performance is the adoption rate of its Aquablation therapy among urologists. The company's strategy involves growing its install base of robotic systems and increasing system utilization by establishing Aquablation therapy as the preferred surgical treatment for benign prostatic hyperplasia (BPH). As of the end of 2025, PROCEPT BioRobotics had a global install base of 912 AquaBeam and HYDROS robotic systems, with 718 located in the United States. The company is also focused on broadening private payor coverage and building a strong base of clinical evidence to support the use of Aquablation therapy.

Operationally, PROCEPT BioRobotics continues to invest in research and development to drive continuous improvements and innovation in its technologies. The company is currently developing additional and next-generation technologies to support and improve Aquablation therapy, with a focus on enhancing usability and scalability. These efforts include leveraging treatment data and software development capabilities to integrate artificial intelligence and machine learning for improved treatment planning and personalization. As of December 31, 2025, the company had 888 employees, reflecting its ongoing expansion and investment in its workforce.

Looking ahead, PROCEPT BioRobotics aims to further penetrate existing international markets and expand into new ones. While the United States remains the primary focus in the near term, the company is growing its presence in other markets by promoting the clinical benefits of Aquablation therapy, supporting investments in clinical studies to improve coverage and reimbursement, and fostering relationships with key opinion leaders. The company plans to strategically invest in new markets based on assessments of market size, opportunity, and reimbursement prospects. The company believes that its existing cash and cash equivalents and anticipated revenue will be sufficient to meet its capital requirements and fund its operations through at least the next 12 months.

About PROCEPT BioRobotics Corp

Procept Biorobotics develops advanced surgical robotic systems for minimally invasive urologic procedures, primarily treating benign prostatic hyperplasia (BPH). Its flagship products, AquaBeam and HYDROS systems, utilize proprietary waterjet technology for precise, safe, and durable tissue removal. The company targets hospitals and urologists worldwide, emphasizing clinical evidence, personalized treatment planning, and broad reimbursement support to improve patient outcomes and establish a new standard in BPH surgery.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.